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Abstract
Introduction The aim of this study was to assess the efficacy of
two dosing schedules of recombinant human erythropoietin
(rHuEPO) in increasing haematocrit (Hct) and haemoglobin
(Hb) and reducing exposure to allogeneic red blood cell (RBC)
transfusion in critically ill patients.
Method This was a prospective, randomized, multicentre trial. A
total of 13 intensive care units participated, and a total of 148
patients who met eligibility criteria were enrolled. Patients were
randomly assigned to receive intravenous iron saccharate alone
(control group), intravenous iron saccharate and subcutaneous
rHuEPO 40,000 units once per week (group A), or intravenous
iron saccharate and subcutaneous rHuEPO 40,000 units three
times per week (group B). rHuEPO was given for a minimum of
2 weeks or until discharge from the intensive care unit or death.
The maximum duration of therapy was 3 weeks.
Results The cumulative number of RBC units transfused, the
average numbers of RBC units transfused per patient and per
transfused patient, the average volume of RBCs transfused per
day, and the percentage of transfused patients were
significantly higher in the control group than in groups A and B.
No significant difference was observed between group A and B.
The mean increases in Hct and Hb from baseline to final
measurement were significantly greater in group B than in the
control group. The mean increase in Hct was significantly
greater in group B than in group A. The mean increase in Hct in
group A was significantly greater than that in control individuals,
whereas the mean increase in Hb did not differ significantly
between the control group and group A.
Conclusion Administration of rHuEPO to critically ill patients
significantly reduced the need for RBC transfusion. The
magnitude of the reduction did not differ between the two
dosing schedules, although there was a dose response for Hct
and Hb to rHuEPO in these patients.
Hb = haemoglobin; Hct = haematocrit; ICU = intensive care unit; RBC = red blood cell; rHuEPO = recombinant human erythropoietin.Critical Care    Vol 9 No 5    Georgopoulos et al.
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Introduction
Anaemia is a common problem in critically ill patients [1,2].
Indeed, it has been shown that, at intensive care unit (ICU)
admission, mean haemoglobin (Hb) concentration in critically
ill patients is about 11 g/dl, and in 60% and 30% of them the
mean Hb is less than 12 and 10 g/dl, respectively. Thus, the
majority of critically ill patients exhibit anaemia upon ICU
admission, which persists throughout the duration of their ICU
stay. Overt or occult blood loss and decreased production of
red blood cells (RBCs) due to blunted erythropoietic response
are the two main causes of anaemia in these patients [3].
Anaemia in critically ill patients results in significant RBC trans-
fusions. Approximately 40% of critically ill patients receive at
least one unit of RBCs, relatively soon after ICU admission
[1,2]. It is of interest that the mean number of RBC units trans-
fused approaches five and the pretransfusion Hb is about 8.5
g/dl, indicating that the large number of transfusions is not due
to a high transfusion threshold for Hb [1,2].
It has been recognized that RBC transfusion is not without
risks. The adverse effects of RBC transfusions are numerous,
including transmission of infection [4], transfusion associated
immunosuppression [5-9], transfusion related acute lung injury
[10], disturbances in microcirculation due to blood storage
[11,12] and allergic reactions [9]. Large observational studies
in critically ill patients have shown that RBC transfusion is an
independent risk factor for increased mortality [1,2]. Although
the mechanism through which RBC transfusion may increase
mortality is currently unknown, studies have shown that RBC
transfusion in critically ill patients is associated with a higher
incidence of infection and evidence of tissue hypoxia
[11,13,14]. These data indicate that the likely contributing fac-
tors to mortality are related to immunosuppression and distur-
bances in microcirculation, as opposed to allergic reaction or
transmission of infection.
Because of the risks associated with blood transfusion, alter-
native treatments and preventative strategies for anaemia in
critically ill patients have been explored. Among them, exoge-
nous administration of recombinant human erythropoietin
(rHuEPO) demonstrated promising results [15-17]. The
rationale underlying therapy with rHuEPO therapy in critically
ill patients is that increased erythropoiesis will result in higher
Hb levels and subsequently reduce the need for RBC transfu-
sion [18]. It has been shown that exogenous rHuEPO in criti-
cally ill patients raised reticulocyte counts and Hb, and
reduced considerably requirements for RBC transfusion [15-
17].
The two randomized studies that showed that rHuEPO is effi-
cacious in increasing Hb level and reducing allogeneic RBC
transfusion used two different therapeutic regimens [15,16].
One study [16] used 300 units/kg rHuEPO for 5 consecutive
days and then every other day to achieve a haematocrit (Hct)
concentration above 38%, whereas in the other [15] the drug
was administered weekly in a dose of 40,000 units. Thus, the
optimal dose of rHuEPO in critically ill patients is not known,
which is an issue of financial importance, given the cost of this
therapy.
The aim of the present study was to assess the efficacy of two
dosing schedules of rHuEPO (40,000 units once and thrice
per week, respectively) in increasing Hct and Hb and in reduc-
ing exposure to allogeneic RBC transfusion in critically ill
patients. These dosing regimens are comparable to those
used by the two randomized studies in critically ill patients
[15,16].
Materials and methods
This study was a prospective, randomized, multicentre trial
conducted at 13 Greek ICUs between November 2000 and
December 2003. Approval of the study was given by the insti-
tutional review committee at each participation centre and
written informed consent was obtained from each patient or
next of kin. Patient enrollment was done at each site and
supervised by the data coordinating centre. Randomization
and data analysis were done by the data coordinating centre.
A stratified random sampling scheme was employed as the
selection method for randomization. Acute Physiology and
Chronic Health Evaluation II score and age decades were con-
sidered as distinct strata. To ensure equal allocation of individ-
uals from each stratum (epsem scheme), the sampling fraction
was considered. The sample size was calculated in order to
detect a 10% difference in the Hct values between groups
receiving rHuEPO at a 5% significance level and 90% power,
assuming that the mean Hct for the group receiving the lowest
dose would be in the range of 35% and the variance equal to
30.
All patients admitted to the ICU in each of the 13 participating
centres were evaluated for study eligibility. Inclusion criteria
were as follows: age at least 18 years; Hb less than 12 g/dl;
no iron deficiency (defined as transferrin saturation <10% and
ferritin <50 ng/ml); negative pregnancy test (for females of
reproductive age); an expected ICU stay of at least 7 days;
and provision of signed informed consent. The expected dura-
tion of the ICU stay was judged on clinical grounds and Acute
Physiology and Chronic Health Evaluation II score by the ICU
team at admittance to the unit. Exclusion criteria included
chronic renal failure requiring dialysis, new onset (<6 months)
seizures, life expectancy under 7 days, previous use of
rHuEPO (within 3 months), recent use of cytostatics or recent
radiotherapy (within 1 month) and participation in another
research protocol.
The patients were randomly assigned (day 0) to receive intra-
venous iron saccharate alone (control group), intravenous iron
saccharate and subcutaneous rHuEPO 40,000 units once per
week (group A), and intravenous iron saccharate andAvailable online http://ccforum.com/content/9/5/R508
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subcutaneous rHuEPO 40,000 units three times per week
(group B). In all groups iron was given at a dose of 100 mg
three times per week. rHuEPO was provided by the sponsor
of the trial.
rHuEPO was given for a minimum of 2 weeks or until ICU dis-
charge or death. The maximum duration of therapy was 3
weeks. rHuEPO was temporarily withheld when Hb exceeded
12 g/dl and was resumed if Hb again fell to below 12 g/dl.
rHuEPO was given intravenously if the platelet count was
below 20,000 µL.
Transfusion of RBCs was standardized at a Hb of 7 g/dl and,
in cases of active cardiac ischaemia and central nervous sys-
tem damage, at 9 g/dl [19]. In patients with active blood loss,
defined as evidence of ongoing blood loss accompanied by a
decrease in the Hb concentration of 3.0 g/dl in the preceding
12 hours or a requirement for at least 3 units of packed RBCs
during the same period, the need for blood transfusion was
determined by the patient's attending physician. The physi-
cians caring for the patients were instructed to administer
RBC transfusions, one unit at a time, and to measure the
patient's Hb concentration after each unit was transfused.
The primary outcome end-points were differences in Hct and
Hb between groups and transfusion independence between
study days 1 and 28. Additional data recorded included ICU
length of stay and cumulative mortality through to day 28.
Adverse effects were assessed daily. Nosocomial infections
were diagnosed using standard criteria [20,21].
All patients were followed up for a total of 28 days from the day
of randomization, unless death occurred earlier. Patients dis-
charged from the hospital before study day 28 had final labo-
ratory data obtained within 5 days of study day 28. Patients
were followed up for 28 days, unless death occurred earlier.
Patients who were discharged from the hospital before study
day 28 and were not available to provide the final laboratory
data (i.e. data were not available within 5 days of study day 28)
were considered lost to follow up. Analysis of outcomes was
on an intent-to-treat basis.
All categorical variables were summarized by frequency distri-
bution tables and analyzed by χ 2 tests. Descriptive results for
continuous measurements were presented as mean ± stand-
ard deviation unless otherwise stated. The methods used for
analysis were analysis of variance F tests, Scheffe tests for
multiple comparisons, Kruskal–Wallis and Mann–Whitney
tests where appropriate. The transfusion rate was analyzed
using a zero-inflated Poisson model. All computations were
done using Sigmastat-plus (SPSS, INC, Chicago, Ill). All sta-
tistical tests were two-sided, and the level of statistical signifi-
cance was set at 5%.
Patients who did not receive a transfusion at the time of study
withdrawal, who died, or who were lost to follow up after hos-
pital discharge were considered nontransfused for the analy-
sis. The number of RBC units transfused, transfusion rate,
average days transfused and units per transfused patient were
analysed using the Mann–Whitney test. Transfusion rate,
expressed as the number of RBC units transfused per day dur-
ing the study, was determined by dividing the number of trans-
fused units for each group by the total number of days alive for
the patients in the group. Average days transfused was deter-
mined by dividing the number of transfusion days for each
group by the total number of days alive for the patients in the
group. The average number of units transfused was deter-
mined by dividing the number of transfusions for each group
by the total number of patients in the group. Units per trans-
fused patient were determined by dividing the number of trans-
fusions for each group by the total number of patients
transfused in the group.
Results
A total of 148 patients were enrolled in the study (Fig. 1).
Forty-eight patients were randomly assigned to the control
group, 51 to group A (40,000 units of rHuEPO once per
week) and 49 to group B (40,000 units of rHuEPO three times
per week). At baseline the demographic characteristics and
severity of the disease did not differ significantly between
groups (Table 1). All patients were mechanically ventilated at
the time of enrollment. This was because the attending physi-
cians did not expect an ICU stay to exceed 7 days if the patient
did not need mechanical ventilatory support at the time of
randomization.
The pretransfusion Hct and Hb did not differ significantly
between groups, averaging 24.5 ± 3.2%, 24.1 ± 2.7% and
23.5 ± 1.8%, and 7.9 ± 1.1 g/dl, 7.6 ± 0.8 g/dl and 7.7 ± 0.9
g/dl, respectively, in the control group, group A and group B.
The cumulative number of RBC units transfused, the average
RBC units transfused per patient and per transfused patient,
and the average volume of RBC transfused per day were sig-
nificantly higher in the control group than in groups A and B,
whereas the differences between groups A and B were not
significant. Also, the percentage of transfused patients was
significantly higher in control group than in groups A and B
(Table 2). Noncompliance of physicians with the transfusion
strategy, as indicated by a finding of pretransfusion Hb 0.5 g/
dl higher than the transfusion threshold, occurred on 10 occa-
sions in control group (7% of the total units transfused in con-
trol group), on seven in group A (21%) and on three (13%) in
group B (P > 0.05).
Transfusion rate represents the mean transfusion per patient
per day. Because of the presence of many zeros, a zero-
inflated Poisson distribution was deemed suitable for model-
ling the data [22]. This is approximately equivalent to using two
separate analyses. The first is the percentage of patients withCritical Care    Vol 9 No 5    Georgopoulos et al.
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no transfusion requirement and the second is the fit of a Pois-
son regression to the data for the transfused patients only. The
percentages of patients with no need for transfusion were
41.7%, 62.7% and 73.5% for the control group, group A and
group B, respectively. The percentage in group B was statisti-
cally different from that in the control group (Fisher's exact test
with Bonferroni correction, P = 0.002). The percentage in
group A did not differ significantly from those in group B and
the control group. Considering the transfusion rate for the
transfused patients only, group A exhibited the lowest value
(22.8 ml). This value was significantly different from the corre-
sponding transfusion rates for patients of group B (32.5 ml; P
< 0.001) and the control group (59.3 ml; P < 0.001).
There was a dose response of Hb and Hct to rHuEPO, which
was evident from study days 14 to 28 (Table 3). The mean
Figure 1
Study flow chart Study flow chart.
Table 1
Demographics and baseline characteristics (at day 0)
Characteristic/parameter Control group Group A Group B
Number of patients 48 51 49
Age (years [median, range]) 58 (19–86) 60 (19–91) 63 (22–88)
Sex (n)
Men 33 41 39
Women 15 10 10
APACHE II score (mean ± SD) 14.4 ± 6.1 14.4 ± 5.3 14.9 ± 5.9
Admitting diagnosis (n)
Trauma 12 19 20
Surgical 9 6 11
Nonsurgical 27 26 18
Baseline laboratory values (day 0)
Hct (% [mean ± SD]) 28.3 ± 3.7 28.2 ± 3.7 28.4 ± 2.8
Hb (g/dl [mean ± SD]) 9.2 ± 1.3 9.3 ± 0.9 9.3 ± 1.2
Reticulocytes (% [mean ± SD]) 3.0 ± 4.2 3.1 ± 3.2 3.6 ± 4.4
Iron (µg/dl [mean ± SD]) 41.3 ± 23.0 46.2 ± 37.1 39.7 ± 24.4
Ferritin (ng/dl [mean ± SD]) 590.6 ± 454.3 453.5 ± 443.1 561.3 ± 489.5
Transferrin saturation (% [mean ± SD]) 23.7 ± 13.1 22.3 ± 12.6 24.8 ± 12.7
The three groups were comparable at enrollment (P > 0.05) with respect to baseline demographic characteristics, admitting diagnosis, severity 
score and laboratory values. APACHE, Acute Physiology and Chronic Health Evaluation; Hct, haematocrit; Hb, haemoglobin; SD, standard 
deviation.Available online http://ccforum.com/content/9/5/R508
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increase in Hct (∆ Hct) and Hb (∆ Hb) from baseline to the final
measurement was significantly greater in group B than in the
control group (Table 2). ∆ Hct was significantly higher in group
B than in group A. ∆ Hct in group A was significantly higher
than in control individuals, whereas ∆ Hb did not differ signifi-
cantly between the control group and group A (Table 2).
There was no significant difference in lengths of ICU and hos-
pital stay among the three groups. Mean ICU length of stay
averaged 21.8 ± 8.2, 21.0 ± 8.3 and 19.6 ± 8.8 days in the
control group, group A and group B, respectively (P > 0.05).
Seven patients stayed in the ICU for less than 7 days, two of
whom were in the control group and five were in group B.
Exclusion of these patients did not materially alter the results
(22.5 ± 7.4, 21.0 ± 8.3 and 21.3 ± 7.5 days, respectively, in
the control group, group A and group B). There was a weak
relationship between the total transfusion need (in ml) and
length of ICU stay (r = 0.162, P = 0.05). Again, exclusion of
the seven patients who stayed in the ICU for less than 7 days
did not change that relationship. Also, mean ICU free days did
not differ between groups, averaging 6.3 ± 8.2 days in the
control group, 7.0 ± 8.3 days in group A and 8.5 ± 8.8 days
in group B. There was no significant difference in mean venti-
lator free days among groups (10.3 ± 10.6 days in the control
group, 11.1 ± 11.5 days in group A and 11.9 ± 10.4 days in
group B).
Seven, five and ten patients died, respectively, in the control
group, group A and group B, resulting in corresponding mor-
tality rates of 14.6%, 9.8% and 20.4% (P > 0.05). The inci-
dence of serious adverse events reported was comparable
between the three groups (Table 4). At least one adverse
event occurred in 23 patients (48.8%) in the control group, in
21 (41.2%) in group A and in 22 (45.8%) in group B.
Table 2
Study outcomes
Parameter Control Group A Group B
Total units transfused 138 33* 23*
% of transfused patients 58.3 37.3* 26.5*
Units transfused per patient 2.83 ± 3.9 0.64 ± 1.0* 0.47 ± 0.9*
Units transfused per transfused patient 4.86 ± 4.0 1.74 ± 0.7* 1.77 ± 0.7*
Volume of RBCs transfused per day 43.2 ± 61.1 11.3 ± 20.3* 16.1 ± 36.1*
Average days transfused 1.60 ± 2.2 0.59 ± 0.9* 0.35 ± 0.7*
Hct (%) at day 28 30.4 ± 4.5 33.3 ± 5.3* 37.5 ± 5.8* †
Hb (mg/dl) at day 28 9.9 ± 1.5 10.7 ± 1.9 11.6 ± 1.9*
∆ Hct (%) 2.09 ± 5.0 5.53 ± 5.5* 8.76 ± 6.2* †
∆ Hb (mg/dl) 0.69 ± 1.5 1.43 ± 1.7 2.24 ± 6.2*
*P < 0.05 versus control; †P < 0.05 versus group A. ∆ Hb, mean increase in Hb from baseline to final measurement; ∆ Hct, mean increase in Hct 
from baseline to final measurement; Hb, haemoglobin; Hct, haematocrit; RBC, red blood cell.
Table 3
Haematocrit and haemoglobin on different study days
Day Haematocrit Haemoglobin
Control Group A Group B Control Group A Group B
0 28.3 ± 3.7 28.2 ± 3.7 28.4 ± 2.8 9.2 ± 1.3 9.3 ± 1.2 9.2 ± 0.9
3 27.9 ± 3.7 26.7 ± 5.0 28.2 ± 3.7 9.1 ± 1.3 9.0 ± 1.1 9.1 ± 1.2
7 28.4 ± 4.1 28.4 ± 3.7 29.5 ± 4.0 9.1 ± 1.4 9.2 ± 1.2 9.5 ± 1.3
10 28.8 ± 4.5 29.4 ± 4.1 30.3 ± 4.2* 9.4 ± 1.6 9.6 ± 1.2 9.7 ± 1.4
14 28.8 ± 4.5 30.8 ± 4.5 32.3 ± 5.4* 9.4 ± 1.4 10.0 ± 1.5 10.3 ± 1.9*
21 29.4 ± 6.2 31.9 ± 5.0 36.5 ± 6.3* † 9.7 ± 2.0 10.3 ± 1.7 11.3 ± 2.1*
28 30.4 ± 4.5 33.3 ± 5.3 37.5 ± 5.8* † 9.9 ± 1.5 10.6 ± 1.9 11.6 ± 1.9*
Shown are mean ± standard deviation values for haematocrit and haemoglobin on different study days. *P < 0.05 versus control; †P < 0.05 versus 
group A.Critical Care    Vol 9 No 5    Georgopoulos et al.
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Discussion
The main findings of our study were as follows: in critically ill
patients rHuEPO administration significantly reduced the
need for RBC transfusions; the magnitude of this reduction
did not differ between the two dosing schedules; and there
was a dose response of Hct and Hb to rHuEPO in these
patients.
The study was not blinded and this might be a limitation. The
designers of the study considered it unethical to administer
placebo subcutaneously to critically ill patients. However, we
believe that this limitation is unlikely to have influenced the
results. Contrary to other studies dealing with rHuEPO admin-
istration in critically ill patients [15,16], in our study a specific
transfusion threshold was applied. Indeed, the indications for
transfusion were predefined and based on objective indices
[19]. This is further supported by the similar value of pretrans-
fusion Hb and Hct in the three groups of patients, indicating
that our results cannot be accounted for by different transfu-
sion strategies between groups. In addition, the rate of failure
of physicians to adhere to the predefined transfusion trigger
was comparable between the three groups. These factors
suggest that the lack of blinding was not a significant con-
founding factor.
In both dosing regimens rHuEPO was given in much higher
doses than are used in patients who are not critically ill [23].
However, it is well known that the requirement for erythropoi-
etin is increased in patients with severe illness [24]. In addi-
tion, the studies that found an effect of rHuEPO on
erythropoiesis in critically ill patients [15-17] used doses in the
range of 40,000 to approximately 120,000 units per week,
which are comparable to those given in our study.
In our study 58% of patients randomly assigned to the control
group received transfusion, and on average they received
approximately 5 units of RBCs. These findings are remarkably
similar to those reported by other studies [1,2] and emphasize
the great number of ICU patients who need RBC transfusion.
We also showed that exogenous administration of rHuEPO to
ICU patients at a dose of 40,000 units once or thrice per week
was able to reduce the number of transfused patients by 36%
and 55%, respectively. Similar results were also reported by
two randomized studies showing that rHuEPO at a dose of
300 units/kg for 5 days followed by administration every other
day [15] or 40,000 once weekly [16] decreased the number
of transfused critically ill patients by approximately 18%. We
further showed that the reduction in the proportion of trans-
fused patients, the total and daily RBC units transfused, the
transfused RBC units per patient and per transfused patient,
and the average days transfused did not differ between the
two dosing regimens. The similar reduction in the need of
transfusion indicates that if the purpose of the administration
of rHuEPO is to reduce RBC transfusion in critically ill
patients, then 40,000 once weekly is probably sufficient.
Higher doses increase the cost of therapy considerably,
whereas on the other hand they are unlikely to have significant
impact on transfusion needs. However, we should note that
these results were obtained with predefined indications for
transfusion based on a certain restrictive transfusion strategy
that is currently recommended [19]. Different results might
have been obtained if other transfusion strategies were used.
It is believed that critically ill patients have limited ability to
compensate for the fall in Hb concentration [25,26]. Indeed, in
these patients anaemia is associated with increased morbidity
and mortality, particularly in patients with pre-existing cardiac
disease [25,26]. Transfusion of RBCs may not be the ideal
therapy for these patients because there is a growing body of
evidence indicating that RBC transfusion in critically ill
patients is an independent risk factor for increased morbidity
and mortality [1,2]. In addition, it has been shown that in the
majority of critically ill patients the transfused blood is relatively
old (>10 days) [2] and this may limit the ability of transfused
RBCs to increase the supply of oxygen to tissues [11]. The
immunomodulatory effects of blood transfusion is also of great
concern in critically ill patients in whom the risk for infections
is high. It was recently shown in patients undergoing hip
replacements that the levels of natural killer cell precursors
and interferon-γ  were substantially reduced by the surgery and
blood loss and by transfusions of allogeneic nonleucode-
pleted, allogeneic leucodepleted, and autologous predeposit
blood [5]. Considering that critically ill patients are often immu-
noparalyzed [27], the immunosuppressive effects of blood
Table 4
Serious adverse events
Adverse event Control Group A Group B
Deaths 751 0
Nosocomial infection 21 22 26
Heart rate and rhythm disorders 3 2 2
Thrombocytosis 1 - 1
Deep vein thrombosis 2 - 1
Central nervous system disorders (new ischaemic or haemorrhagic stroke) 3 2 2Available online http://ccforum.com/content/9/5/R508
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transfusion should be taken into account. Thus, preventing
anaemia by administration of rHuEPO minimizes the risks for
anaemia but without exposing the critically ill to the deleterious
effect of RBC transfusion. Studies have shown that rHuEPO
can achieve this goal [15-17]. We further demonstrated a
dose response of Hct and Hb to rHuEPO; Hct and Hb
increased with increasing dose of rHuEPO. It is of interest that
the final values of Hb and Hct achieved with the highest dose
of rHuEPO were close to normal. It follows that if the goal of
rHuEPO therapy is to attain normal values of Hct and Hb, then
40,000 units thrice per week may be a reasonable strategy.
Corwin and coworkers [28] showed that administration of
rHuEPO in critically ill patients at a dose of 40,000 once per
week was not associated with increased side effects. These
findings are further extended by our study, demonstrating that
rHuEPO even at higher doses of 40,000 three times per week
is probably safe; no significant difference was observed
between rHuEPO groups and the control group in terms of
side effects. Nevertheless, the sample size was relatively small,
and so comments regarding safety should be made with great
caution.
It is currently unclear whether administration of rHuEPO in crit-
ically ill patients is associated with improved outcome. Our
study was underpowered to demonstrate an effect of rHuEPO
on mortality or resource utilization (i.e. length of ICU or hospital
stay, and ICU and ventilator free days). Nevertheless, Corwin
and coworkers [28] reported that neither morbidity nor mortal-
ity differed significantly between critically ill patients receiving
rHuEPO 40,000 once per week and a placebo group. How-
ever, interpretation of these results is complicated by the fact
that the majority of patients receiving rHuEPO were anaemic
by the end of the study, and Hb level differed slightly between
groups (approximately 0.3 g/dl). Considering the relationship
between the level of anaemia and morbidity and mortality
[25,26], the inability of this rHuEPO regimen to increase Hb to
normal levels might have influenced the morbidity and mortality
data. Perhaps doses of rHuEPO that result in near normal val-
ues of Hb and Hct such as those used in the present study (i.e.
40,000 units three times per week) may be associated with
improved outcome. Further studies with the appropriate power
are needed to resolve this issue.
Finally, we should emphasize that the present study was
designed to evaluate the efficiency of two dosing regimens of
rHuEPO in increasing Hb and Hct and decreasing transfusion
requirements, and not to collect pharmacoeconomic data.
Although the study provides some data such as length of stay
and pharmaceutical treatment, it is very difficult to estimate
precisely the cost of overall medical services because Greek
National Health System prices are underestimated because of
the fact that the System is based on very low charges for
patients, largely subsidized by taxation.
Conclusion
In conclusion, the present study showed that administration of
rHuEPO reduces the need for RBC transfusion in critically ill
patients. The magnitude of this reduction was similar between
the two dosing schedules. On the other hand, rHuEPO
increased Hb and Hct in a dose dependent manner. These
results indicate that dose of rHuEPO in critically ill patients
should be titrated depending on the desired goal.
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